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Abstract
Diffuse alveolar haemorrhage related to an anti-neutrophil cytoplasmic antibody (ANCA)-
associated small vessel vasculitis is an extremely rare form of presentation of breast cancer. 
Here we report the case of a 77-year-old woman with a histological diagnosis of a papillary 
ductal carcinoma of the breast presenting with a diffuse alveolar haemorrhage secondary to 
a perinuclear ANCA-associated vasculitis. To our knowledge, this is the first case ever report-
ed of a diffuse alveolar haemorrhage related to an ANCA-associated small vessel vasculitis as 
a form of presentation of breast cancer. The therapeutic approach of this paraneoplastic vas-
culitis included the use of corticosteroids and plasmapheresis, a very useful technique to re-
move endothelial aggressors (circulating antibodies) as a strategy to earn time for a proper 
therapeutic decision specifically directed for disease modification, but that can also be asso-
ciated with several severe adverse effects, which are illustrated in our case.
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Introduction
Breast cancer (BC) is the most common cause of cancer-related death in women around 
the world [1]. The clinical presentation of a breast malignancy is frequently composed by a 
constellation of signs and symptoms that include change in breast shape, skin alterations, 
nipple inversion, single duct discharge, and an axillary dump [2]. A paraneoplastic vasculitis, 
especially an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, is a rare 
form of presentation of BC. In fact, leukocytoclastic vasculitis is the most frequent type of 
cancer-associated vasculitis, most commonly related to haematological malignancies [3]. 
Regardless of the type of vasculitis and the type of malignancy that it is associated with, para-
neoplastic vasculitides are very uncommon forms of cancer presentation.
Here we report the case of a 77-year-old woman with a histological diagnosis of a papillary 
ductal carcinoma of the breast presenting with a diffuse alveolar haemorrhage (DAH) 
secondary to a perinuclear ANCA (p-ANCA)-associated vasculitis.
Case Presentation
A 77-year-old woman was admitted to the emergency department with a 2-week history 
of persistent dry cough and progressive severe fatigue associated with three episodes of frank 
haemoptysis in the previous 24 h. She had also recently noticed a small hard lump in the right 
breast that was painful to touch. She recalled having skin lesions with characteristics 
compatible with purpura in the lower limbs 6 months before, which she assumed were related 
to an antivertigo drug as they disappeared as soon as she stopped taking it. She denied any 
other symptoms.
The patient had a medical history of hypertension, dyslipidaemia, hyperuricemia, and 
peripheral vestibular disorder, and was accordingly treated with bisoprolol, lercanidipine, 
losartan/hydrochlorothiazide, allopurinol, and betahistine.
Initial assessment revealed normal vital signs (with an oxygen saturation of 97% on 
room air). She had skin and mucosae pallor, discrete rales in the bases of both hemithoraxes, 
two nodular, hard, and adherent lesions in the upper inner quadrant and peri-areolar region 
of the right breast, no identifiable adenopathies, and no skin lesions. A complete blood count 
showed a normocytic and normochromic anaemia, with a haemoglobin value of 7 g/dL, and 
a slightly elevated NT-proB-type natriuretic peptide value (657 pg/mL).
Urinary Sediment Examination Showed Haematuria and Proteinuria
The arterial blood gas analysis only revealed mild hypoxemia and the chest radiograph 
showed a bilateral peri-hilar parenchymal infiltrate, located in the inferior two-thirds of the 
pulmonary fields (Fig. 1).
A computed tomography (CT) angiogram of the thorax was then performed, revealing 
diffuse, bilateral, ground-glass opacities predominantly located in the inferior and posterior 
segments of the lungs, which are features compatible with DAH (Fig. 2).
The patient was admitted to the intermediate care unit for adequate clinical surveillance 
and later on transferred to an internal medicine ward. A flexible bronchoscopy confirmed the 
presence of blood in the tracheobronchial tree without a visible focal haemorrhagic point. 
Bacteriological and mycological exams were negative, and no neoplastic cells were found on 
cytological analysis of the bronchoalveolar lavage.
The immunoserological studies showed high titres of ANCA, both myeloperoxidase 
(MPO; >134 U/mL) and proteinase-3 (PR3; 4.5 U/mL), positive anti-nuclear antibodies (ANA) 
with a nucleolar pattern, positive mitosis and a titre of 1:320, normal C3, C4, and CH50 levels, 
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negative anti-GBM, anti-dsDNA, anti-CCP antibodies, normal rheumatoid factor levels, and 
negative serological testing for HIV and hepatotropic viruses (Table 1).
Dermatology observation excluded any skin lesions that could potentially be biopsied. 
Regarding the documented haematuria and proteinuria, a renal ultrasound was performed 
showing no alterations. The nephrology team was consulted to evaluate the eligibility of the 
patient for a renal biopsy. The result of the urinary sediment examination was discredited, as 
it was performed shortly after algaliation, with subsequent urinary sediment examination 
being normal. Renal function evaluations were always normal. Renal involvement was 
considered to be unlikely and it was considered that there was no indication for renal biopsy. 
A bilateral mammary ultrasound and digital mammography revealed benign alterations of 
Fig. 1. The patient’s chest radiograph 
when admitted to the emergency de-
partment.
Fig. 2. CT angiogram of the thorax af-
ter admission.
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the left breast (BI-RADS 2) and suspected malignant alterations of the right breast (BI-RADS 
4C; Fig. 3).
Senology experts performed microbiopsies of both lesions of the right breast that were 
compatible with a papillary ductal carcinoma. Thoracoabdominal-pelvic CT scan and bone 
scintigraphy were clear. For further complementation of the vasculitis study, a sinus CT scan 
and an electromyogram were required and were normal.
At this point it was considered that the most likely diagnosis was of a paraneoplastic 
p-ANCA-associated small vessel vasculitis secondary to a papillary ductal carcinoma of the 
right breast. During the rest of the patient’s hospital stay there was a clinical deterioration 
with a new episode of haemoptysis, subsequent worsening of her anaemia, and a clear imago-
logical proof (a new thoracic CT angiogram was performed; Fig. 4) of DAH aggravation.
The patient was initially treated with pulse therapy with methylprednisolone (1 g/day) 
for 3 days and, after that, with prednisolone (1 mg/kg/day). The potential benefit of plasma-
pheresis was discussed as a way of removing the circulating p-ANCA and, consequently, 
earning time for a more specifically directed therapeutic approach to the BC. Accordingly, a 
cycle of nine sessions of plasmapheresis (five on consecutive days, and four on alternate days) 
was proposed, in association with the ongoing therapy with oral corticosteroids.
Only six sessions were completed due to several adverse effects, particularly significant 
hypofibrinogenemia, severe thrombocytopaenia (minimum of 15,000 platelets) and anaemia 
(haemoglobin minimum value of 6.2 g/dL), managed with fibrinogen (2 g), red blood cell (1 
unit) and human immunoglobulin (30 g) administration. A new CT angiogram of the thorax 
showed an impressive decrease of the DAH extension (Fig. 5).
Following a mammary magnetic resonance imaging (MRI) of the right breast (Fig. 6) and 
the discussion of the case in the multidisciplinary oncology meeting, a radical mastectomy 
with sentinel lymph node biopsy was suggested.
ANCA-MPO Positive (>134 U/mL)












ANCA-MPO, myeloperoxidase anti-neutrophil cytoplasmic anti-
bodies; ANCA-PR3, proteinase 3-anti-neutrophil cytoplasmic anti-
bodies; ANA, anti-nuclear antibodies; C3, complement component 3; 
C4, complement component 4; CH50, 50% haemolytic complement 
activity of serum; anti-GBM, anti-glomerular basal membrane anti-
bodies; anti-dsDNA, anti-double stranded DNA antibodies; anti-CCP, 
anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; 
anti-HIV 1/2, anti-HIV 1 and 2 antibodies; AgHBs, hepatitis B surface 
antigen; anti-HCV, anti-hepatitis C antibodies.
Table 1. Laboratory 
immunoserological investigation
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Fig. 3. Digital mammography showing 
suspected malignant alterations of the 
right breast (BI-RADS 4C; a) and be-
nign alterations of the left breast (BI-
RADS 2; b).
Fig. 4. CT angiogram of the thorax per-
formed during hospitalization, reveal-
ing aggravation of the extent of DAH.
Fig. 5. CT angiogram of the thorax per-
formed after six sessions of plasma-
pheresis, revealing an impressive de-
crease of the extent of DAH.
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Further clinical improvement was observed, and the patient was discharged. Internal 
medicine, autoimmune diseases, and general surgery appointments were arranged after 
discharge. The patient was submitted to a radical mastectomy with sentinel lymph node 
biopsy 2 months after, which was uneventful.
The anatomical-pathological examination of the surgical sample revealed an invasive, 
micropapillary carcinoma, G2, with extensive haemorrhagic areas, and a diameter of 2.7 cm. 
The adjacent parenchyma had lesions of focal adenosis, and aspects compatible with invasive 
ductal carcinoma. Lymphangiosis was observed, with no angioneuro invasion, ER >95%, PR 
>95%, HER2 –, Ki67 <10%. The surgical margins were tumour free, and the TNM stage was 
pT2, pN0.
A CT angiogram of the thorax was performed 2 weeks after the surgery, showing complete 
resolution of DAH (Fig. 7). No distant disease (metastasis) was present. The case was again 
discussed in the multidisciplinary meeting of BC and the patient was treated with letrozole 
and zoledronic acid, without any side effects. Unexpectedly, the patient died at home 
presumably due to complications related to concurrent atrial fibrillation (which had been 
diagnosed after hospital discharge).
Discussion
To our knowledge, this is the first case ever reported of a DAH related to an ANCA-asso-
ciated small vessel vasculitis as a form of presentation of BC. There are some other cases that 
report an episode of DAH as a manifestation of a concomitant disease in a patient with a 
previous diagnosis of BC and that associate DAH as a short- or long-term complication of the 
treatment (chemotherapy and radiotherapy) for BC.
The connection between BC and scleroderma renal crisis (SRC) complicated with DAH 
and pleuro-pericardial effusions was previously reported in a patient who had already been 
diagnosed (5 months before) with stage IIB BC. When the SRC manifestations arose, the 
patient had already had a bilateral mastectomy with lymph node resection and had not 
received systemic anti-neoplastic therapy [4].
Fig. 6. MRI of the right and left breasts.
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The development of DAH caused by sequential adjuvant chemoradiotherapy for BC was 
also described in a female patient with BC (an adenocarcinoma of the left breast, pT1cN0M0) 
originally treated with conserving surgery and subsequently with adjuvant radiotherapy and 
chemotherapy. The symptoms related with the evolving DAH appeared 9 days after the third 
administration of docetaxel and cyclophosphamide (3 months after the final irradiation) [5].
The occurrence of DAH secondary to pulmonary angiosarcoma in post-irradiation and 
post-radical mastectomy patients is mentioned in the literature. Angiosarcoma arising, 
several years later, at post-irradiation sites is a well-described phenomenon [6].
DAH consists of diffuse bleeding in the alveolar space. It is defined by the triad of diffuse 
alveolar infiltrates, haemoptysis, and dropped haematocrit, followed by increased diffusion 
capacity by 30% [7]. In the present case episodes of frank haemoptysis were reported, and 
radiographic and tomographic evidence of diffuse alveolar infiltrates and a dropped haema-
tocrit were verified.
Causes of DAH can be inflammatory or non-inflammatory. Inflammatory DAH may be due 
to ANCA-associated vasculitis with pulmonary capillaritis. There are different genetic, infec-
tious, and immunological factors that interact and play a role in the aetiology of pulmonary 
vasculitis [7–10].
The immunoserological studies of the patient showed high titres of ANCA, both MPO and 
PR3, and positive ANA. There was not a previous diagnosis of lupus erythematosus or any 
manifestations that could suggest it. The anti-dsDNA antibodies were negative, the complement 
levels were normal, the exam of the urinary sediment was normal, the renal function remained 
stable, and the anti-MBG antibodies were negative. The most plausible cause for the DAH was 
an ANCA-associated vasculitis.
Fig. 7. CT angiogram of the 
thorax performed 2 weeks 
after radical right mastec-
tomy.
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ANCAs are IgG-type antibodies against cytoplasmic antigens of neutrophils and mono-
cytes (MPO and PR-3) [7]. The ANCA-associated vasculitis comprise granulomatosis with 
polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. 
Typical features of granulomatosis with polyangiitis include nasal crusting, stuffiness and 
epistaxis, upper respiratory tract involvement, and often, when in the context of an active 
urinary sediment, renal involvement. Patients with microscopic polyangiitis are typically 
older and present with more severe renal involvement, rash, and neuropathy. Eosinophilic 
granulomatosis with polyangiitis typically presents as a multisystem disease on a background 
of asthma, nasal polyposis, and peripheral blood eosinophilia [11].
In this case, the titres of ANCA were not useful for distinguishing between the different 
types of ANCA-associated vasculitis, since both MPO and PR3 antibodies titres were high. 
Given the absence of nasal and upper respiratory tract involvement, asthmatiform symptoms, 
and peripheral blood eosinophilia, a microscopic polyangiitis was considered the most likely 
diagnosis.
The association between cancer and vasculitis is uncommon and, conceptually, hard to 
establish as it is particularly difficult to define the temporal relationship necessary to draw 
valid conclusions [3]. Certain cancers may cause a plethora of signs and symptoms that are 
not linked with tumour invasion and compression [12, 13], syndromes that were labelled 
“paraneoplastic” in the 1940s [12, 14]. These syndromes are attributed to tumour secretion 
of functional peptides and hormones or immune cross-reactivity between tumour and normal 
host tissues [12].
In 1986, Longley et al. [15, 16] suggested that malignant neoplasms might produce 
antigens and consequently cause paraneoplastic vasculitis. In the same year, McLean [15, 17] 
defined two criteria to establish the presence of paraneoplastic vasculitis: first, the simulta-
neous appearance of both vasculitis and neoplasm, and second, their parallel course. Some of 
the suggested mechanisms for the development of paraneoplastic vasculitis are the production 
of immunoglobulins directed to the abnormal tumour cells and also the normal endothelium; 
abnormal production of immunoglobulins that can react to vascular antigens causing 
formation of in situ immune complexes; release of various cytokines that can cause endo-
thelial injury; induction of a delayed hypersensitivity reaction by deposition of cancer proteins 
on vessel walls, and overrun of vessel walls. Concomitant precipitating events (infections, 
drugs) may also cause an immune complex-mediated disorder that can be observed even at 
the beginning of the neoplastic disease [15–21].
Paraneoplastic vasculitides are estimated to represent 2–5% of all vasculitis [3, 22, 23]. 
In an 18-year study, 12 patients were diagnosed with both cancer and vasculitis in the same 
12-month period [3, 24]. In a 10-year study, 60 patients had a diagnosis of vasculitis asso-
ciated with malignancies [3, 22]. Hematologic malignancies were one of the most common 
type of malignancies in both studies, accounting for 50 and 63% of cancers respectively. 
Carcinomas of the urinary tract accounted for 40% of solid tumours associated with para-
neoplastic vasculitis [3, 23]. Leukocytoclastic vasculitis is the most commonly reported para-
neoplastic vasculitis [3, 22–24]. There is only a cancer-specific association with a vascu- 
litis – hairy cell leukaemia and polyarteritis nodosa [3, 25]. ANCA-associated vasculitides 
have rarely been described as paraneoplastic manifestations [3].
Regarding this case, the appearance of skin lesions reported by the patient 6 months 
before the admission may be related to the antivertigo drug (given the temporal rela-
tionship), even though one cannot exclude the possibility of them already being cancer mani-
festations. The diagnosis of DAH due to an ANCA-associated vasculitis was concomitant with 
the diagnosis of BC, which supports the paraneoplastic nature of this vasculitis. The singu-
larity of this case is also underlined by the type of paraneoplastic vasculitis (opposed to 
leukocytoclastic vasculitis, ANCA-associated vasculitis has rarely been described as a para-
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neoplastic manifestation) and the type of cancer involved. In fact, in contrast to hematologic 
and some solid organ malignancies, such as the carcinomas of the urinary tract, BC is rarely 
associated with paraneoplastic syndromes [26]. Nevertheless, when present, these can occur 
at any point in the disease’s course, even preceding formal diagnosis in some cases [26, 27]. 
It is also interesting to note that the majority of studies that correlate ANCA-associated 
vasculitis with an increased cancer risk attribute this to the use of cytotoxic medications for 
the treatment of the vasculitis, especially cyclophosphamide (a known carcinogen asso-
ciated with an increased risk for bladder cancer, acute leukaemia, and skin cancer [28]), 
which was not the case.
The recommended treatment for ANCA-associated vasculitis comprises both remission 
induction and maintenance phases. The induction of remission may be achieved by the use of 
daily glucocorticoids plus cyclophosphamide or rituximab. Other regimens using metho-
trexate or mycophenolate mofetil should only be an option for patients without evidence of 
organ dysfunction or life-threatening disease. In patients presenting with creatinine >500 
μmol/L, the addition of plasma exchange to high-dose glucocorticoids and cyclophosphamide 
or rituximab should be considered [11]. After successful remission induction, guidelines 
recommend withdrawing the initial immunosuppressive agent and commencing a mainte-
nance regimen with either azathioprine or methotrexate [9, 29, 30].
In the present case, we opted to initially treat the patient with pulse therapy with meth-
ylprednisolone and, after that, with prednisolone. We did not include cyclophosphamide in 
the remission induction therapeutic scheme as there was, by that time and as previously 
mentioned, a deterioration of the patient’s clinical status.
We decided to commence plasma exchange, even though the patient did not meet the 
recommended criteria, as a way of removing the circulating p-ANCA and earning time for a 
more specifically directed therapeutic approach to the, by that time, probable BC. A cycle of 
nine sessions of plasmapheresis was programmed and combined with the ongoing therapy 
with oral corticosteroids. Our case highlights that plasma exchange can be a very useful tech-
nique to remove endothelial aggressors, but several significant adverse effects may be asso-
ciated with the procedure and must be taken into consideration. In fact, our patient only 
completed six sessions because of hypofibrinogenemia, severe thrombocytopaenia, and 
severe anaemia, which were treated accordingly.
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